Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Economic burden and healthcare resource utilization
9 evidence topics · 9 sources
Cost increase at progression to castration resistance
“Among 296 patients with mCSPC progressing to mCRPC (median age 69.0 years, 60.5% White, 15.9% Black)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean number of days with PC-related outpatient visits increased from 1.57 to 2.16 PPPM in the mCSPC and mCRPC disease states (P < 0.001). From the mCSPC to mCRPC disease states, mean all-cause total health care costs PPPM increased from $4,424 (medical costs: $2,846) to $9,717 (medical costs: $4,654), and mean PC-related total health care costs PPPM increased from $2,859 (medical costs: $1,626) to $8,012 (medical costs: $3,285; all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs during first-line therapy: commercial, Medicare Advantage, and Medicaid claims
“Among 459 patients with mCRPC (mean age 70 years, 57% White, 16% Black, 45% commercially-insured, 43% Medicare Advantage-insured, and 12% Medicaid-insured), average baseline all-cause total costs (PPPM) were $4,576 ($4,166 pre-mCRPC progression, $8,278 post-mCRPC progression).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During an average 1 L duration of 8.5 months, mean total costs were $13,746 (all-cause) and $12,061 (PC-related) PPPM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PC-related medical costs PPPM increased from $1,504 during baseline to $5,585 following 1 L mCRPC therapy initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare fee-for-service resource use by line of therapy
“A total of 14,780 men with mCRPC were identified. After mCRPC diagnosis, 11,528 men initiated 1L mCRPC therapy, 6275 initiated 2L, and 2945 initiated 3L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause medical HRU (days PPPY) increased after mCRPC diagnosis and from 1L through 3L treatment, particularly for outpatient care (pre-diagnosis, 10.4; 1L, 16.2; 2L, 18.9; 3L, 22.0) and physician/other visits (pre-diagnosis, 30.1; 1L, 46.5; 2L, 50.2; 3L, 56.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After mCRPC diagnosis, 11,528 (78%) patients received life-prolonging therapy and 3252 (22%) patients did not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare fee-for-service costs by line of therapy
| Period | All-cause medical and pharmacy, mean per patient per year (2019 USD) | Prostate cancer-related medical, mean per patient per year (2019 USD) |
|---|---|---|
| Year before mCRPC diagnosis | “27,468”View highlighted excerpt for this quote | “11,411”View highlighted excerpt for this quote |
| After mCRPC diagnosis, all patients | “124,379”View highlighted excerpt for this quote | “52,609”View highlighted excerpt for this quote |
| After diagnosis, no life-prolonging therapy | “102,380”View highlighted excerpt for this quote | “51,076”View highlighted excerpt for this quote |
| First line | “148,325”View highlighted excerpt for this quote | “69,063”View highlighted excerpt for this quote |
| Second line | “160,118”View highlighted excerpt for this quote | “73,467”View highlighted excerpt for this quote |
| Third line | “165,186”View highlighted excerpt for this quote | “95,240”View highlighted excerpt for this quote |
Older Medicare beneficiaries: resource use and costs per patient-year
“A total of 4758 patients met the eligibility criteria and received 1L treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, patients had 1.2 inpatient admissions, 1.1 emergency room visits, and 27.6 outpatient visits per year during follow-up. The mean total all-cause and PC-related costs during the follow-up period were $111,060 and $99,540 per-patient-per-year, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Second androgen receptor pathway inhibitor or taxane after a first: resource use in Medicare
“Patients with mCRPC who previously received one androgen receptor pathway inhibitor (ARPI) followed by either a second ARPI (ARPI cohort) or a taxane (taxane cohort) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 923 patients, 714 were in the ARPI cohort and 209 in the taxane cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was ≈1 year in both cohorts. SAEs were more frequent in the taxane cohort (66.0% vs 42.2%; p < 0.001). The taxane cohort had more ER, outpatient, and pharmacy visits (p < 0.0001), while the ARPI cohort had more hospitalizations (p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Taxane adverse event costs after first-line androgen receptor pathway inhibitor
“Overall, 2L ARPI (n = 473) vs. taxane (n = 214) was associated with longer median OS (15.4 vs. 13.6 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, only 22% of patients in the Flatiron cohort and 13% in the PharMetrics cohort received > 8 cycles of taxanes, while 78% and 87%, respectively, were early discontinuers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insurer drug payments by first-line agent: employer-sponsored insurance
“This retrospective cohort study included 4,298 patients with prostate cancer who initiated therapy with one of six drugs approved for first-line treatment of mCRPC between July 1, 2013, and June 30, 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over the 6 months after the index prescription, mean unadjusted gross drug payments were highest for patients receiving sipuleucel-T ($115,525 USD) and lowest for patients using docetaxel ($12,804 USD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events: attributable Medicare cost
“HCRU and costs (in 2013 U.S. dollars) were evaluated in a propensity score-matched cohort by using Poisson regression and Kaplan-Meier sample average estimators, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 3,297 men with prostate cancer metastatic to bone, 40% experienced ≥1 SRE (median follow-up, 19 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among men with ≥1 SRE, emergency department visits were twice as frequent (95% CI, 1.77–2.28) and hospitalizations were nearly four times as frequent (95% CI, 3.20–4.40). The attributable cost of ≥1 SRE was $21,191 (≥1 SRE: $72,454 [95% CI, $67,362–$76,958]; SRE-free: $51,263 [95% CI, $45,439–$56,100]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote